Lowering the sirna delivery barrier: Alginate scaffolds and immune stimulation

Nanotechnology for the Delivery of Therapeutic Nucleic Acids

Volumn , Issue , 2013, Pages 193-216

  McCaskill, Jana ^a   Wu, Sherry ^a   Khairuddin, Norliana ^a   McMillan, Nigel A J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881685682     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814411059     Document Type: Chapter

References (78)

1. Fire, A., et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998. 391(6669): pp. 806-811.
2. Gao, S., et al., The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther, 2009. 17(7): pp. 1225-1233.
3. Soutschek, J., et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004. 432 (7014): pp. 173-178.
4. Watts, J.K., G.F. Deleavey, and M.J. Damha, Chemically modified siRNA: tools and applications. Drug Discov Today, 2008. 13(19-20): pp. 842-855.
5. Yuan, H., et al., Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol, 2008. 295(2): pp. F605-617.
6. McNamara, J.O., 2nd, et al., Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 2006. 24(8): pp. 1005-1015.
7. Kim, S.S., et al., Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med, 2009. 15(11): pp. 491-500.
8. Schwarze, S.R., et al., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999. 285(5433): pp. 1569-1572.
9. Torchilin, V.P., et al., TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA, 2001. 98(15): pp. 8786-8791.
10. Kumar, P., et al., Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007. 448(7149): pp. 39-43.
11. Moschos, S.A., et al., Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem, 2007. 18(5): pp. 1450-1459.
12. Kim, H.K., et al., Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm, 2010. 392(1-2): pp. 141-147.
13. Vangasseri, D.P., S.J. Han, and L. Huang, Lipid-protamine-DNA-mediated antigen delivery. Curr Drug Deliv, 2005. 2(4): pp. 401-406.
14. Gao, K., and L. Huang, Nonviral methods for siRNA delivery. Mol Pharm, 2009. 6(3): pp. 651-658.
15. Li, S.D., S. Chono, and L. Huang, Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther, 2008. 16(5): pp. 942-946.
16. Pirollo, K.F., et al., Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res, 2007. 67(7): pp. 2938-2943.
17. Shim, M.S., and Y.J. Kwon, Controlled delivery of plasmid DNA and siRNA to intracellular targets using ketalized polyethylenimine. Biomacromolecules, 2008. 9(2): pp. 444-455.
18. Thomas, M., et al., Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci USA, 2005. 102(16): pp. 5679-5684.
19. Tan, P.H., et al., Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther, 2005. 12(1): pp. 59-66.
20. Guo, S., F. Huang, and P. Guo, Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther, 2006. 13(10): pp. 814-820.
21. Alshamsan, A., et al., Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm, 2009. 6(1): pp. 121-133.
22. Zintchenko, A., et al., Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug Chem, 2008. 19(7): pp. 1448-1455.
23. Howard, K.A., et al., Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther, 2009. 17(1): pp. 162-168.
24. Nawroth, I., et al., Intraperitoneal administration of chitosan/dsiRNA nanoparticles targeting TNFalpha prevents radiation-induced fibrosis. Radiother Oncol, 2010. 97(1): pp. 143-148.
25. Howard, K.A., et al., RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther, 2006. 14(4): pp. 476-484.
26. Zhang, W., et al., Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med, 2005. 11(1): pp. 56-62.
27. Tiemann, K., and J.J. Rossi, RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med, 2009. 1(3): pp. 142-151.
28. Wu, S.Y., et al., Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res, 2009. 26(3): pp. 512-522.
29. Zhang, Y., et al., Engineering mucosal RNA interference in vivo. Mol Ther, 2006. 14(3): pp. 336-342.
30. Ogris, M., et al., PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther, 1999. 6(4): pp. 595-605.
31. Akinc, A., et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol, 2008. 26(5): pp. 561-569.
32. Judge, A.D., et al., Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest, 2009. 119(3): pp. 661-673.
33. Li, S.D., and L. Huang, Targeted delivery of antisense oligodeoxynuc-leotide and small interference RNA into lung cancer cells. Mol Pharm, 2006. 3(5): pp. 579-588.
34. Matsumura, Y., and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 1986. 46(12 Pt 1): pp. 6387-6392.
35. Jeffs, L.B., et al., A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res, 2005. 22(3): pp. 362-372.
36. Yu, W., et al., A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther, 2004. 11(19): pp. 1434-1440.
37. Morrissey, D.V., et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol, 2005. 23(8): pp. 1002-1007.
38. Zimmermann, T.S., et al., RNAi-mediated gene silencing in non-human primates. Nature, 2006. 441(7089): pp. 111-114.
39. Geisbert, T.W., et al., Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet, 2010. 375(9729): pp. 1896-1905.
40. Podesta, J.E., and K. Kostarelos, Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery. Methods Enzymol, 2009. 464: pp. 343-354.
41. Buyens, K., et al., Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes. Langmuir, 2009. 25(9): pp. 4886-4891.
42. Shi, N., R.J. Boado, and W.M. Pardridge, Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res, 2001. 18(8): pp. 1091-1095.
43. Maurer, N., et al., Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J, 2001. 80(5): pp. 2310-2326.
44. Stuart, D.D., and T.M. Allen, A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta, 2000. 1463(2): pp. 219-229.
45. Wu, S.Y., et al., Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther, 2011. 18(1): pp. 14-22.
46. Cristofaro, P., and B. Ramratnam, RNAi tackles a sexually transmitted disease. Nat Biotechnol, 2006. 24(1): pp. 48-49.
47. Cone, R.A., Barrier properties of mucus. Adv Drug Deliv Rev, 2009. 61(2): pp. 75-85.
48. Kanazawa, T., et al., Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine. Int J Pharm, 2008. 360(1-2): pp. 164-170.
49. Palliser, D., et al., An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature, 2006. 439(7072): pp. 89-94.
50. Wu, Y., et al., Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe, 2009. 5(1): pp. 84-94.
51. Woodrow, K.A., et al., Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater, 2009. 8(6): pp. 526-533.
52. Wu, S.Y., et al., Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. J Control Release, 2011. 155(3): pp. 418-426.
53. Khanna, K.V., et al., Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest, 2002. 109(2): pp. 205-211.
54. Gillgrass, A.E., et al., Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol, 2003. 77(18): pp. 9845-9851.
55. Kaushic, C., et al., Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol, 2003. 77(8): pp. 4558-4565.
56. de la Fuente, M., et al., Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine (Lond), 2008. 3(6): pp. 845-857.
57. Mittal, S.K., et al., Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine, 2000. 19(2-3): pp. 253-263.
58. Krebs, M.D., O. Jeon, and E. Alsberg, Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. J Am Chem Soc, 2009. 131(26): pp. 9204-9206.
59. LeRoux, M.A., F. Guilak, and L.A. Setton, Compressive and shear properties of alginate gel: effects of sodium ions and alginate concentration. J Biomed Mater Res, 1999. 47(1): pp. 46-53.
60. Lim, S.H., I.C. Liao, and K.W. Leong, Nonviral gene delivery from nonwoven fibrous scaffolds fabricated by interfacial complexation of polyelectrolytes. Mol Ther, 2006. 13(6): pp. 1163-1172.
61. Hong, H.J., et al., Accelerated wound healing by smad3 antisense oligonucleotides-impregnated chitosan/alginate polyelectrolyte complex. Biomaterials, 2008. 29(36): pp. 4831-4837.
62. Patnaik, S., et al., PEI-alginate nanocomposites as efficient in vitro gene transfection agents. J Control Release, 2006. 114(3): pp. 398-409.
63. Brake, T., et al., Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res, 2003. 63(23): pp. 8173-8180.
64. Takeuchi, O., and S. Akira, Innate immunity to virus infection. Immunol Rev, 2009. 227(1): pp. 75-86.
65. Marques, J.T., and B.R. Williams, Activation of the mammalian immune system by siRNAs. Nat Biotechnol, 2005. 23(11): pp. 1399-1405.
66. Clemens, M.J., PKR-a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol, 1997. 29(7): pp. 945-949.
67. Hornung, V., et al., 5'-Triphosphate RNA is the ligand for RIG-I. Science, 2006. 314(5801): pp. 994-997.
68. Robbins, M., et al., Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Human Gene Ther, 2008. 19(10): pp. 991-999.
69. Flynn, M.A., et al., Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond), 2004. 1(1): p. 4.
70. Ge, Q., et al., Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA, 2004. 101(23): pp. 8676-8681.
71. Song, E., et al., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 2005. 23(6): pp. 709-717.
72. Tompkins, S.M., et al., Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA, 2004. 101(23): pp. 8682-8686.
73. Furset, G., and M. Sioud, Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun, 2007. 352(3): pp. 642-649.
74. Nguyen, D.N., et al., Drug delivery-mediated control of RNA immunostimulation. Mol Ther, 2009. 17(9): pp. 1555-1562.
75. Anz, D., et al., Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol, 2010. 184(2): pp. 939-946.
76. Poeck, H., et al., 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med, 2008. 14(11): pp. 1256-1263.
77. Kortylewski, M., et al., In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol, 2009. 27(10): pp. 925-932.
78. Khairuddin, N., et al., siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol, 2012. 90(2): pp. 187-196.